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Abstract
Purpose To study if second-generation antipsychotic (S-GA) use during pregnancy is associated with an increased risk of
pregnancy and neonatal complications.
Methods A population-based birth cohort study using national register data extracted from the “Drugs and Pregnancy” database
in Finland, years 1996–2016. The sampling frame included 1,181,090 pregnant women and their singleton births. Women were
categorized into three groups: exposed to S-GAs during pregnancy (n = 4225), exposed to first-generation antipsychotics (F-
GAs) during pregnancy (n = 1576), and unexposed (no purchases of S-GAs or F-GAs during pregnancy, n = 21,125). Pregnancy
outcomes in S-GA users were compared with those in the two comparison groups using multiple logistic regression models.
Results Comparing S-GA users with unexposed ones, the risk was increased for gestational diabetes (adjusted odds ratio, OR
1.43; 95% CI 1.25–1.65), cesarean section (OR 1.35; 95% CI 1.18–1.53), being born large for gestational age (LGA) (OR 1.57;
95% CI 1.14–2.16), and preterm birth (OR 1.29; 95% CI 1.03–1.62). The risk for these outcomes increased further with
continuous S-GA use. Infants in the S-GA group were also more likely to suffer from neonatal complications. Comparing S-
GA users with the F-GA group, the risk of cesarean section and LGAwas higher (OR 1.25, 95%CI 1.03–1.51; and OR 1.89, 95%
CI 1.20–2.99, respectively). Neonatal complications did not differ between the S-GA and F-GA groups.
Conclusions Prenatal exposure to S-GAs is associated with an increased risk of pregnancy complications related to impaired
glucose metabolism. Neonatal problems are common and occur similarly in S-GA and F-GA users.
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Introduction
Use of the second-generation antipsychotics (S-GAs) has in-
creased during the last decades. This tendency is evident not
only on population level but also within the pregnant popula-
tion. In the USA, the prevalence of use of S-GAs during preg-
nancy increased from 0.4 to 1.3% in 2001–2010, while the use
of first-generation antipsychotics (F-GAs) remained stable at
around 0.1% [1]. The increased use of S-GAs may be related
to the argued, but not uniformly proven, better tolerability or a
more favorable side-effect profile when compared with that of
F-GAs [2]. Off-label use, including use as hypnotics and sed-
atives, may also play a role. There are no published data on
use of antipsychotics during pregnancy in Finland.
Several S-GAs—contrary to FGAs—have minor effect on
prolactin secretion [3] and pregnancies may occur more easily
during treatment. Use of S-GAs may predispose to hypergly-
cemia [3, 4], and maternal gestational diabetes increases the
risk of several pregnancy complications including being born
large for gestational age (LGA). While some previous studies
have reported an increased risk of gestational diabetes [5–7] or
LGA [8, 9] associated with S-GA use, not all studies have
confirmed these associations [10–13]. Use of S-GAs during
pregnancy has also been associated with increased risk of
being born small for gestational age (SGA) [10], low birth
weight [14], and preterm birth [9, 10, 12, 15], but results have
been conflicting [5, 13]. Antipsychotic drugs can further give
rise to neonatal symptoms reflected in poor Apgar score or
need for treatment in the neonatal care unit. Even though S-
GA treatment is suspected to increase the risk of pregnancy
complications, changing effective medication is rarely possi-
ble as maternal well-being is a prerequisite for a favorable
pregnancy outcome. Because of the increasing use of S-GAs
among pregnant women and conflicting data on their safety,
we investigated the association between S-GA use during
pregnancy and pregnancy and neonatal complications using
nationwide register data.
Methods
This is a population-based birth cohort study using national
register data extracted from the existing Drugs and Pregnancy
database, established by the National Institute for Health and
Welfare (THL), the Social Insurance Institution of Finland
(Kela), and the Finnish Medicines Agency (FIMEA) [16].
The objective of the database is continuous surveillance of drug
safety during pregnancy by using the Medical Birth Register,
the Abortion Register, the National Register of Congenital
Malformations, and the Prescription Register, including also
the Special Refund Entitlement Register. Data from these reg-
isters have been linked by the personal identification number
assigned to all citizens and permanent residents in Finland. Data
from births and terminations of pregnancy, and prescription
drug purchases have been collected since 1 Jan. 1996. The
beginning of pregnancy has been calculated from the best clin-
ical estimation of gestational age at birth, primarily based on
ultrasound. Pregnancy trimesters are divided into first (until 84
days’ gestation), second (days 85–182), and third (days 183
until birth).
The Medical Birth Register (MBR) maintained since 1987
by THL is a nationwide register collecting data on maternal
demographic characteristics, medical and reproductive histo-
ry, smoking, diagnoses during pregnancy and delivery, and
neonatal outcome data up to 6 days’ age. Data in the MBR
includes all live births and stillbirths with gestational age of 22
weeks or more or birth weight of 500 g or more, and the
completeness of births is close to 100% [17–19]. The defini-
tions and variables included in this registry are based on
established international concepts and use the 10th version
of the WHO International Classification of Diseases (ICD)
since 1996 (children) and 2004 (mothers).
The Finnish Prescription Registry (Kela) contains data on
reimbursed prescription drug purchases [20]. Prescription-
only medicines deemed necessary for the treatment of an ill-
ness are reimbursed under the national social insurance which
covers all permanent residents in Finland. Drug purchases are
reimbursed concomitantly upon purchase at pharmacies, and
drugs are supplied to the patient for a maximum of 3 months at
a time. Data in the register include the date of the purchase and
the International Anatomical-Therapeutic-Chemical (ATC)
classification code indicating the generic name of the drug
(https://www.who.int/classifications/atcddd/en/). Over-the-
counter drugs or medications given to institutionalized per-
sons are not included in the register. The Kela also maintains
the Special Refund Entitlement Register since 1964 with data
on patients who are entitled for higher reimbursement for
chronic illnesses requiring continuous drug treatment.
Definition of exposed and unexposed cohorts
This study frame included 1,181,090 pregnancies ending in
singleton birth in Finland between 1 Jan. 1996 and 31
Dec. 2016 recorded in the Drugs and Pregnancy database
(Fig. 1). Exposed to S-GAs: women who purchased S-GAs
(olanzapine, quetiapine, risperidone, aripiprazole, clozapine,
ziprasidone, sertindole, or asenapine; Supplementary
Table S1) at any time during pregnancy or 1 month before
pregnancy (n = 4225). Continuous use of S-GAs: women
who purchased S-GAs in at least two trimesters (n = 2135).
Unexposed: pregnant women who had no purchases of S-GAs
or F-GAs during the period of 1 month prior to pregnancy until
the end of pregnancy. Controls in this group were matched for
year of birth of child (± 1 month) and were randomly selected
as five controls for one exposed (5:1) (n = 21,125). Exposed to
F-GAs: women who purchased F-GAs (Supplementary
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Table 1) but did not purchase S-GAs during the same period (n
= 2126). This comparison group was included to control for
maternal psychiatric illness. Pregnancies that were only ex-
posed to prochlorperazine (n = 550) were excluded because it
is mostly used for morning sickness, leaving 1576 women in
the F-GA group for analyses. Continuous use of F-GAs: wom-
en who purchased F-GAs in at least two trimesters (n = 722).
Maternal characteristics and covariates
Covariates included maternal demographic, social and medi-
cal characteristics, and use of other drugs, categorized as
shown in Table 1. Data on prepregnancy BMI were available
only beginning from 2004 and for all women from September
2005. Alcohol use is not routinely collected in the MBR and
could therefore not be included in analyses.
Outcome variables
The outcomes related to pregnancy and delivery included hy-
pertension of pregnancy (ICD-10 diagnoses O10, O11, O16 or
MBR hypertension record), gestational diabetes (ICD-10 di-
agnoses O24.4 and O24.9, pathological glucose tolerance test
orMBR diabetes record with no information on pregestational
diabetes), breech presentation, cesarean section, small for ges-
tational age (SGA, birth weight of more than two standard
deviations less than the sex- and length-of-gestation-specific
national standards), large for gestational age (LGA, birth
weight of more than two standard deviations more than the
sex- and length-of-gestation-specific national standards) [21],
categorically defined late preterm (32–36 gestational weeks)
and very preterm birth (< 32 weeks), shoulder dystocia, and
stillbirth. Neonatal outcomes included 1- and 5-min Apgar
scores < 7, monitoring in neonatal care or neonatal intensive
care unit (NCU), hospitalization at 7 days age, neonatal death,
and post-neonatal death (Fig. 1).
Statistical analyses
All data in the Drugs and Pregnancy database are
pseudonymized. The prevalence of specific outcomes was
compared between the S-GA group, the unexposed group,
and the F-GA group. Univariate analyses were used to
study demographic differences between the study cohorts,
and the logistic regression to assess the association be-
tween S-GA use during pregnancy and pregnancy and peri-
natal outcomes.
The crude model included adjustment for year of deliv-
ery. For the adjusted analyses, clinically relevant and plau-
sible covariates were first tested for association with the
three-class exposure status. When associated with expo-
sure at significance level p < 0.1, the covariate was further
tested separately for association with each outcome. For
each of the 16 outcomes, we included in the logistic re-
gression model covariates which were associated with ex-
posure and outcome at p < 0.1 as potential confounders
(Supplementary Table S2). We also analyzed third trimes-
ter use separately for neonatal outcomes. All analyses were
performed in SAS (SAS 12.1, NC, USA).
The utilization of sensitive health register data for scien-
tific research and the data linkages in the “Drugs and
Pregnancy” project have been approved by the register ad-
ministrators and the national data protection authority. The
study protocol was approved by the Institutional Review
Board at the National Institute for Health and Welfare
(THL). Since the study subjects are not contacted, according
to the Finnish legislation, informed consent is not required
for large register studies. The study was registered in The
European Network of Centres for Pharmacoepidemiology
and Pharmacovigilance (ENCePP) register before data col-
lection started (EUPAS4799). The study has been granted
the ENCePP seal, following the ENCePP principles of stan-
dards, transparency, and independence of good
pharmacoepidemiology practice throughout the research
process (www.encepp.eu).
Idenﬁcaon of pregnant women who had a singleton pregnancy 
ending in delivery (1996-2016)
N = 1,181,090
S-GA use during pregnancy
n=4,225
F-GA use during pregnancy
n= 1,576
Pregnancy complicaons (live and sllbirths): 
Hypertension; Gestaonal diabetes; Breech presentaon; Cesarean secon; Small
for gestaonal age; Large for gestaonal age;  Preterm birth; Very preterm birth; 
Shoulder dystocia; Sllbirth
Neonatal complicaons (live births): 
Apgar 1 and 5 min<7; Neonatal or intensive care; Hospitalizaon in 7 days; Neonatal 
and post-neonatal death
Unexposed
n= 21,125
Fig. 1 Flow chart of the exposure
and outcome information used in
the study
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Results
Overall, the prevalence of any antipsychotic use in 1,181,090
singleton births was 0.5% during pregnancy or 30 days before
it. S-GAs have basically replaced the use of F-GAs among
pregnant women during the last 20 years (Fig. 2). A total of
4225 (0.4%) women purchased S-GAs during pregnancy or
30 days before pregnancy, and 2135 (0.2%) had prescription
fills in at least two trimesters. S-GA and F-GA users were two
or three times more frequently smokers than women not using
antipsychotics. Overweight was also more prevalent in S-GA
users than in unexposed women (45.5% vs. 32.8%). Maternal
characteristics of the three study groups are presented in
Table 1.
Pregnancy and delivery diagnoses by exposure status are
presented in Table 2. Compared with that in the unexposed
Table 1 Maternal characteristics. Mothers with a singleton birth (N = 26,926)
Second-generation
antipsychotics (S-GAs)
First-generation
antipsychotics (F-GAs)
Unexposed Covariate associated
with exposure
n % n % n % p value
4225 100.0 1576 100.0 21,125 100.0
Age at delivery < 0.0001
20–34 3113 73.7 1020 64.7 16,539 78.3
< 20 or ≥ 35 1112 26.3 556 35.3 4586 21.7
Parity < 0.0001
No previous deliveries 2176 51.5 637 40.4 8803 41.7
1 or more previous deliveries 2049 48.5 939 59.6 12,322 58.3
Prepregnancy BMI mean, (SD)a 26.3 6.1 26.2 5.8 24.5 5.0 < 0.0001
< 18.5 155 3.7 13 0.8 714 3.4
18.5–24.9 1869 44.2 336 21.3 12,240 57.9
≥25.0 1923 45.5 321 20.4 6918 32.8
Unknown 278 6.6 906 57.5 1253 5.9
Marital status < 0.0001
Married/co-habiting 3154 74.7 1250 79.3 18,862 89.3
Single 704 16.7 195 12.4 1101 5.2
Unknown 367 8.7 131 8.3 1162 5.5
Smoking < 0.0001
No 2299 54.4 923 58.6 17,491 82.8
Yes 1790 42.4 598 37.9 3115 14.8
Unknown 136 3.2 55 3.5 519 2.5
Socioeconomic status < 0.0001
Upper white collar 299 7.1 145 9.2 2724 12.9
Lower white collar 767 18.2 504 32.0 5434 25.7
Blue collar 454 10.8 266 16.9 2126 10.1
Other 876 20.7 384 24.4 2751 13.0
Unknown 1829 43.3 277 17.6 8090 38.3
Exposure to other psychiatric drugsb 2818 66.7 936 59.4 931 4.4 < 0.0001
Exposure to known teratogens 672 15.9 172 10.9 215 1.0 < 0.0001
Maternal illness
Psychotic and other severe mental disorders 1661 39.3 625 39.7 60 0.2 < 0.0001
Pregestational diabetesc 83 2.0 16 1.0 171 0.8 < 0.0001
Other chronic diseases 240 5.7 78 5.0 1355 6.4 0.0198
aData available from 2004
bOther psychiatric drugs, including anxiolytics (ATC codes N05B), hypnotics and sedatives (N05C), antidepressants (N06A), psychostimulants (N06B),
antidepressant-combination preparations (N06C), drugs used in addictive disorders (N07B)
c Diagnoses (ICD 10) E10-E11 and O24.0-O24.1 or medical reimbursement for diabetes, obtained from the Special reimbursement register (Social
Insurance Institution, Kela)
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group, the risk of several pregnancy complications was in-
creased in the S-GA group. The risk of gestational diabetes,
cesarean section, LGA, and preterm birth remained clearly
higher in the S-GA group also after adjustment (Table 2).
Compared with that in the F-GA group, the risk of gestational
diabetes was not increased, while the risk of cesarean section
was 25% higher and LGAwas close to twice as high in the S-
GA group (adjusted OR 1.89; 95% CI 1.20–2.99) (Table 2).
Of the most commonly used S-GAs, the prevalence of gesta-
tional diabetes ranged from 18.6% among risperidone users to
32.8% among clozapine users (Table 3).
Infants in the S-GA group were more likely to receive poor
Apgar scores, to need treatment in neonatal care or intensive
care unit and to be hospitalized at 7 days when compared with
the unexposed group (Table 4). The risk of neonatal compli-
cations did not differ between the S-GA and F-GA groups
(Table 4).
Restricting analyses to women with continuous use of S-
GAs, the risk of gestational diabetes, cesarean section, LGA,
and preterm birth increased further when compared with those
in the unexposed group, while the risk of very preterm birth
was lower (Table 5). Compared with the continuous use F-GA
group, the risk of breech birth in the S-GA users was 2.7-fold,
and the risk of LGA was 2.3-fold. This increased risk of ce-
sarean section did not remain statistically significant after ad-
justment. Regardless of the increased risk of LGA, the risk of
shoulder dystocia in S-GA pregnancies was not increased but
the numbers were small (Table 5). Restricting analyses to third
trimester purchases, the risk of receiving low Apgar scores,
the risk of treatment in neonatal care or intensive care unit, and
the risk of hospitalization at 7 days were further increased in
the S-GA group when compared with those in the unexposed
group. No differences in the risk of neonatal complications
were observed between the S-GA and F-GA groups
(Supplementary Table 3).
Discussion
In this population-based study, S-GA use during pregnancy
was associated with an increased risk of pregnancy complica-
tions, including gestational diabetes, cesarean section, LGA,
and preterm birth when compared with the unexposed group.
The risk for several neonatal complications was also in-
creased. Compared with F-GAs, the risk for cesarean section
was increased by 25%, and the risk for LGAwas nearly 2-fold,
while the risk of neonatal complications did not differ between
these groups.
Previously published studies investigating the safety of S-
GA use during pregnancy have been based on population
registries [5, 11, 22], electronic health records [12, 13], in-
surance data [23], hospital registers [24, 25], and data from
pharmacovigilance and teratology information centers, the
latter typically based on prospectively collected exposure
data [8–10, 26]. A few studies have considered mothers’
psychiatric illness using untreated disease controls, and few
studies have compared different types of antipsychotics [11,
12, 26]. Because of different data sources and research
methods, the results have often been conflicting and are dif-
ficult to compare. However, similarities in certain maternal
characteristics have been observed across the studies.
Mothers using antipsychotics tend to smoke more frequently,
have a higher prepregnancy BMI, and have lower socioeco-
nomic status (SES) than non-users [27, 28]. Smoking, obe-
sity, and lower SES were associated with antipsychotic use
also in our material.
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Use of S-GAs can affect normal glucose metabolism and
induce weight gain by inhibiting the insulin signaling pathway
which leads to insulin resistance and increased insulin produc-
tion, or by direct damage to pancreatic beta cells [29]. During
pregnancy, high maternal blood glucose results in increased
fetal insulin production. Insulin is an anabolic hormone and
promotes fetal growth. Apart from genetically determined
characteristics, maternal diabetes and high prepregnancy BMI
are major risk factors for being born LGA. Previous research
has shown conflicting results: increased risk of gestational dia-
betes was not observed in studies based on prospective inter-
views [28], electronic health records [12], and health adminis-
trative databases [13], while a recent study based on Medicaid
data observed an increased risk of gestational diabetes in wom-
en using olanzapine or quetiapine [1]. Two previous studies
with prospectively collected exposure data reported an in-
creased risk of LGA associated with S-GA use [8, 9], but the
numbers of exposed were too small for meaningful analysis.
Contrary to these, the anticipated increased risk of being born
LGA was not observed in a Swedish population-based cohort
study after prenatal exposure to olanzapine or clozapine, the two
most diabetogenic S-GAs [5]. We observed a 43% increase of
gestational diabetes and a 57% increased risk of LGA in S-GA
users compared with the unexposed ones, and these risks in-
creased further with continuous use of S-GAs. Compared with
that in the F-GA group, the risk of gestational diabetes was not
increased, while the risk of LGAwas increased by nearly 90%.
However, only insulin-treated gestational diabetes was recorded
in the MBR before 2004. Recording of glucose intolerance test
and gestational diabetes diagnoses started only in 2004.
Similarly, recording of maternal height and weight—used in
calculating BMI—did not start until 2004. This coincides with
the change in pattern of S-GA and F-GA use (Fig. 2) and is
reflected in the large number (nearly 60%) of missing data of
Table 2 Pregnancy complications among second-generation antipsychotic (S-GA) users, first-generation antipsychotic (F-GA) users, and unexposed
mothers
Outcome S-GA n =
4225
F-GA n =
1576
Unexposed
n = 21,125
S-GA vs. unexposed S-GA vs. F-GA
n % n % n % Crude
OR
95% CI Adjusted
OR
95% CI Crude
OR
95% CI Adjusted
OR
95% CI
Hypertension 122 3.0 69 9.2 371 1.8 1.67 1.36–2.07 0.98 0.65–1.47 1.07 0.74–1.55 0.90 0.59–1.38
Gestational diabetes 1051 24.9 191 12.1 3047 14.4 1.98 1.83–2.15 1.43 1.25–1.65 1.07 0.87–1.31 0.97 0.78–1.20
Breech birth 122 2.9 29 1.8 527 2.5 1.16 0.95–1.42 1.10 0.90–1.34 1.92 1.13–3.27 1.70 1.00–2.89
Cesarean section 1057 25.0 336 21.3 3251 15.4 1.83 1.70–1.99 1.35 1.18–1.53 1.29 1.07–1.55 1.25 1.03–1.51
Small for
gestational age
223 5.3 96 6.1 779 3.7 1.46 1.25–1.70 1.02 0.80–1.30 0.91 0.65–1.26 0.82 0.58–1.16
Large for
gestational age
159 3.8 46 2.9 455 2.2 1.78 1.48–2.14 1.57 1.14–2.16 1.76 1.13–2.75 1.89 1.20–2.99
Preterm birth
32–36 weeks
295 7.0 97 6.2 794 3.8 1.92 1.68–2.21 1.29 1.03–1.62 0.92 0.68–1.25 0.87 0.63–1.20
Very preterm birth
< 32 weeks
50 1.2 37 2.4 170 0.8 1.48 1.08–2.03 0.78 0.45–1.32 0.87 0.48–1.60 0.78 0.41–1.47
Shoulder dystociaa 13 0.3 3 0.2 52 0.3 1.25 0.68–2.30 1.16 0.62–2.14 0.57 0.13–2.40 0.58 0.14–2.41
Stillbirtha 21 0.5 12 0.8 56 0.3 1.88 1.14–3.11 0.56 0.23–1.32 0.59 0.23–1.52 0.57 0.20–1.61
Missing data on outcome excluded from analyses: hypertension 6.3%, SGA, LGA and cesarean section < 0.1% of pregnancies
OR, odds ratio; CI, confidence interval; Crude OR, adjusted for year of delivery; Adjusted OR, adjusted for year of delivery and covariates associated
with exposure and outcome at p < 0.1 as given in Supplementary Table 2
a Changes in adjusting variables due to small numbers. Shoulder dystocia: BMI and socioeconomic status categories reduced; stillbirth: socioeconomic
status categories reduced
Table 3 Number of pregnancies with second-generation antipsychotic
(S-GA) purchases and gestational diabetes recorded during pregnancy by
drug
S-GA Exposed pregnancies Gestational diabetes
n n %
Quetiapine 3244 799 24.6
Olanzapine 573 170 29.7
Risperidone 317 59 18.6
Aripiprazole 220 71 32.3
Clozapine 119 39 32.8
Ziprasidone 17 1 5.9
Sertindole 7 3 42.9
Asenapine 2 1 50.0
There were no drug purchases for the following S-GAs: paliperidone,
lurasidone, sultopride, remoxipride, amisulpride, levosulpiride,
mosapramine, zotepine, paliperidone, iloperidone, cariprazine, and
brexpiprazole
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BMI in the F-GA group. Thus, completeness of pregestational
and gestational diabetes diagnoses in our material substantially
improves over time, and comparing the risks of gestational di-
abetes and LGA between S-GA and F-GA users is therefore of
limited value. However, the S-GAs are known to pass the
placenta [30] and a direct effect on fetal insulin secretion is
therefore also possible. It could be hypothesized that even in
the absence ofmaternal hyperglycemia, fetal exposure to S-GAs
could cause inhibition of insulin signaling, followed by insulin
resistance and increased insulin secretion in the fetus.
Table 4 Neonatal outcomes among second generation antipsychotic (S-GA) users, first-generation antipsychotic (F-GA) users, and unexposed
mothers
Outcome S-GA, n
= 4204
F-GA, n
= 1564
Unexposed,
n = 21,069
S-GA vs. unexposed S-GA vs. F-GA
n % n % n % Crude
OR
95% CI Adjusted
OR
95% CI Crude
OR
95% CI Adjusted
OR
95% CI
Apgar 1 min 0–6 409 9.8 142 9.1 1160 5.5 1.85 1.65–2.08 1.40 1.15–1.70 1.00 0.77–1.30 0.99 0.75–1.29
Apgar 5 min 0–6 212 6.0 38 6.3 399 2.3 2.75 2.32–3.26 1.82 1.38–2.39 0.86 0.59–1.27 0.81 0.55–1.20
NCU 990 23.6 335 21.4 2134 10.1 2.73 2.51–2.97 1.46 1.27–1.68 1.12 0.93–1.35 0.93 0.77–1.13
Hospitalization at
7 days
602 14.3 233 14.9 1121 5.3 2.98 2.68–3.31 1.52 1.27–1.82 1.26 1.01–1.57 1.02 0.81–1.28
Early neonatal death
(0–6 days)a
4 0.1 7 0.5 19 0.1 1.05 0.36–3.10 0.87 0.20–3.75 0.27 0.05–1.37 0.28 0.05–1.44
Post-early neonatal
death (7–364 days) or
other infant deaths
(7–364 days)
19 0.5 15 1.0 41 0.2 2.33 1.35–4.01 1.43 0.58–3.56 0.49 0.20–1.22 0.43 0.17–1.08
Missing data on outcome excluded from analyses: Apgar 1 min 0.3%, Apgar 5 min 18.4%, hospitalization in 7 days 0.2% of pregnancies
NCU, neonatal care or intensive care unit;OR, odds ratio;CI, confidence interval;Crude OR, odds ratio adjusted for year of delivery; Adjusted OR, odds
ratio adjusted for year of delivery and covariates associated with exposure and outcomes at p < 0.1 as given in Supplementary Table 2
a Changes in adjusting variables due to small numbers: BMI categories reduced
Table 5 Pregnancy complications among second-generation antipsychotic (S-GA) users, first-generation antipsychotic (F-GA) users, and unexposed
mothers during at least two trimesters
Outcome S-GA, n
= 2135
F-GA, n
= 722
Unexposed,
n = 21,125
S-GA vs. unexposed S-GA vs. F-GA
n % n % n % Crude
OR
95% CI Adjusted
OR
95% CI Crude
OR
(95% CI) Adjusted
OR
95% CI
Hypertension 65 3.1 32 9.6 371 1.8 1.87 1.43–2.46 1.02 0.59–1.77 1.39 0.79–2.43 1.37 0.70–2.68
Gestational diabetes 612 28.7 103 14.3 3047 14.4 2.36 2.13–2.62 1.62 1.35–1.95 1.14 0.85–1.52 1.05 0.78–1.42
Breech birth 62 2.9 12 1.7 527 2.5 1.17 0.90–1.53 1.12 0.86–1.47 3.19 1.39–7.32 2.69 1.17–6.16
Cesarean section 571 26.7 173 24.0 3251 15.4 2.01 1.81–2.23 1.56 1.31–1.86 1.34 1.03–1.76 1.31 0.99–1.74
Small for
gestational age
100 4.7 46 6.4 779 3.7 1.29 1.04–1.60 0.94 0.67–1.33 0.75 0.46–1.24 0.69 0.40–1.19
Large for
gestational age
104 4.9 29 4.0 455 2.2 2.34 1.88–2.91 1.77 1.18–2.67 2.17 1.21–3.90 2.28 1.25–4.17
Preterm birth
32–36 weeks
155 7.3 47 6.5 794 3.8 2.00 1.67–2.39 1.51 1.12–2.03 0.97 0.62–1.53 0.95 0.58–1.56
Very preterm birth
< 32 weeks
19 0.9 20 2.8 170 0.8 1.12 0.69–1.80 0.39 0.17–0.90 0.62 0.24–1.59 0.58 0.22–1.53
Shoulder dystociaa 9 0.4 1 0.1 52 0.3 1.71 0.84–3.48 1.56 0.76–3.19 0.95 0.10–9.31 NA
Stillbirtha 9 0.4 7 1.0 56 0.3 1.63 0.81–3.30 0.41 0.12–1.39 0.37 0.10–1.43 0.37 0.08–1.74
Missing data on outcome excluded from analyses: hypertension 4.9%, SGA, LGA, and cesarean section < 0.1% of pregnancies
OR, odds ratio; CI, confidence interval; Crude OR, adjusted for year of delivery; Adjusted OR, adjusted for year of delivery and covariates associated
with exposure and outcome at p < 0.1 as given in Supplementary Table 2
a Changes in adjusting variables due to small numbers. Shoulder dystocia: BMI and socioeconomic status categories reduced; stillbirth: BMI and
socioeconomic status categories reduced
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We observed a nearly threefold increased risk of breech
birth is women who purchased S-GAs in two or more trimes-
ters compared with the F-GA group, but the risk was not
increased when compared with that in the unexposed ones.
This may be a chance finding, as the numbers were small
and the confidence intervals wide. Fetal growth restriction
has been identified as a predictive factor for breech presenta-
tion [31] while LGA has not [32].
Preterm birth was more common in S-GA users than in the
unexposed group, and the risk was further increased, being
51% higher in women with continuous S-GA use. This find-
ing is in contrast to a large Canadian study based on health
administrative data [13]. While we adjusted for several covar-
iates, including use of other psychiatric drugs and entitlement
for special reimbursement for psychosis, we did not have data
on maternal history of previous preterm births. It is also likely
that maternal illness–related factors or illness severity may to
some extent explain this result as the risk was not increased in
comparisons between the S-GA and the F-GA groups. The
lower risk of very preterm birth in S-GA users compared with
the unexposed ones was an unexpected finding. This may be
attributed to methodology as women giving birth in very early
weeks were less likely to fulfill the criteria of purchases in at
least two pregnancy trimesters.
Major strengths in our study include the comprehensive
prospectively acquired data covering all births in the country
during the study period. We adjusted for a high number of
potential confounders obtained from the registers and includ-
ed a comparison group of women using F-GAs during preg-
nancy, controlling to some extent for maternal illness. The
prevalence of antipsychotic drug use and several of the exam-
ined outcomes in our study were comparable with those in
other countries [1, 6, 7, 12], suggesting that the results are
generalizable to other populations. Further, data in the drug
prescription register is virtually complete [20] and as antipsy-
chotics are reimbursed, it is likely that all purchases are in-
cluded in our data. The MBR data have been validated and
found to correspond well with medical records [18, 19]. Due
to the personal identification number awarded at birth or mi-
gration to all citizens, mothers, their drug purchases and chil-
dren are reliably identified in the registers.
Use of register-based data has also limitations, as drug com-
pliance cannot be confirmed. Women often discontinue drugs
when they find out that they are pregnant and this applies also
for antipsychotics [33]. However, we included analyses of
women purchasing S-GAs in at least two trimesters, suggesting
compliance. One limitation is that we have no information on
the severity of maternal illness and the possibility of residual
confounding by behavioral factors, such as alcohol and illicit
drug use, which were not available in the register data. Yet, use
of these substances strongly correlates with smoking included
in our analyses.
Conclusion
Prenatal exposure to S-GAs is associated with an increased
risk of pregnancy complications related to impaired glucose
metabolism. Neonatal problems are common and occur simi-
larly in S-GA and F-GA users.
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